ADMET

Biomarker

Related News

Insilico Medicine Announces AI Foundation Model Partnership and China Drug Development Deal

Mar 04, 2026

Insilico Medicine has formed a strategic partnership with Liquid AI to develop lightweight scientific foundation models for drug discovery and entered a drug development collaboration with China Medical System Holdings targeting CNS and autoimmune diseases.

AI-Designed Drugs Achieve 90% Phase I Success Rate, Nearly Doubling Industry Average

Feb 26, 2026

Drug candidates designed via generative artificial intelligence are achieving a 90% success rate in Phase I safety trials in early 2026, nearly double the historical industry average of approximately 50%, while compressing development timelines from six years to under 18 months.